Dr. Jean-Paul Kress is new CEO of MorphoSys AG
The biotech company is currently establishing its first commercial presence in the US
In June the Supervisory Board of MorphoSys AG appointed Dr. Jean-Paul Kress as its new Chief Executive Officer (CEO) with effect from September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong track record of commercial and operational leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development and especially the commercialization of innovative products. Prior to joining MorphoSys, Dr. Kress worked at Syntimmune, Sanofi Genzyme, Gilead and Eli Lilly. In his new position, Dr. Kress succeeds Dr. Simon Moroney, who stepped down as CEO on September 1, 2019.
Dr. Jean-Paul Kress, CEO, MorphoSys
“I am delighted to welcome Jean-Paul Kress as the new CEO of MorphoSys,” said Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys. “MorphoSys is at a turning point in its business evolution, bringing its first product to the market and establishing a commercial presence in the US. Jean-Paul’s industry expertise will perfectly complement the experienced MorphoSys Management Board.”
“On behalf of the entire Supervisory Board, I want to express our sincere gratitude to Simon Moroney for fulfilling the role as CEO over the past 27 years. His tireless efforts for MorphoSys have contributed substantially to making it the biopharmaceutical success story that it is today.” Marc Cluzel continued.